SHS 006
Alternative Names: SHS-006Latest Information Update: 09 Nov 2022
At a glance
- Originator Nanjing Sanhome Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Nov 2022 Preclinical trials in Cancer in China (Parenteral) before November 2022 (Sanhome pipeline, November 2022)